Immutep Limited
Case Overview
55 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 07/06/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Immutep Limited |
| Court: | Court: Southern District of New York |
| Case Number: | Case Number: 1:26cv03705 |
| Class Period: | Class Period: 03/24/2025 - 03/12/2026 |
| Ticker: | Ticker: IMMP |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Immutep Limited (“Immutep” or the “Company”) (NASDAQ:IMMP) securities during the period of March 24, 2025 through March 12, 2026, inclusive (“the Class Period”).
The lawsuit alleges that the Compny provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its TACTI-004 Phase III clinical trial study.
On March 13, 2026, Immutep issued a press release announcing that the Independent Data Monitoring (IDMC) for the TACTI-004 Phase III study recommended that the trial be discontinued following a planned interim futility analysis. Further, based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility. Following this news, the price of Immutep's ADRs declined dramatically. On this news, the price of Immutep shares declined by $2.28 per share, or approximately 83%, from $2.76 per share on March 12, 2026 to close at $0.48 on March 13, 2026.
The lawsuit alleges that the Compny provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its TACTI-004 Phase III clinical trial study.
On March 13, 2026, Immutep issued a press release announcing that the Independent Data Monitoring (IDMC) for the TACTI-004 Phase III study recommended that the trial be discontinued following a planned interim futility analysis. Further, based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility. Following this news, the price of Immutep's ADRs declined dramatically. On this news, the price of Immutep shares declined by $2.28 per share, or approximately 83%, from $2.76 per share on March 12, 2026 to close at $0.48 on March 13, 2026.